Skip to main content
. 2019 Sep 10;2019:7391237. doi: 10.1155/2019/7391237

Table 2.

Distribution of ER, PR, and HER2 status between the primary tumor and recurrent lesions (N = 67).

Biomarkers ConcordanceN (%) DiscordanceN (%) Total discordanceN (%)
PL (+) PL (−) PL (+) PL (−)
RL (+) RL (−) RL (−) RL (+)
ER 27 (40.3%) 22 (32.8%) 8 (11.9%) 10 (14.9%) 18 (26.9%)
PR 11 (16.4%) 30 (44.8%) 17 (25.4%) 9 (13.4%) 26 (38.8%)
HER2 19 (29.7%) 33 (49.3%) 5 (7.5%) 10 (14.9%) 15 (22.4%)

PL: Primary lesions; RL: Recurrent lesions.